Levosimendan Treatment During Orthotopic Heart Transplantation: Case Report
OZET Kalp trans plan tas yo nu son ra si er ken mor ta li te nin en onem li se bep le rin den bi ri si pri mer greft yet mez li gi dir. Te da vi se ce nek le ri ise; inot rop lar ve me ka nik ola rak des tek le yen arac lar dir. Ye ni bir kal si yum (Ca+2) du yar las ti ri ci ajan olan le vo si men dan; po zi tif inot ro pik, ko ro ner, pul mo ner ve sis te mik va zo di la tor et ki ye sa hip tir. Bu su nu da or to to pik kalp trans plan tas yo nu ge ci ren iki ol gu da du suk kalp de bi si ne de niy le bir ol gu da inot ro pik des te ge, di ger ol gu da inot ro pik ve in tra a or tik ba - lon des te gi ne ek ola rak 12 µg -1 . kg -1 . dk'lik yuk le me do zu nu ta ki ben 0.2 µg -1 .kg -1 .dk'lik in fuz yon do zun da le vo si men dan des te gi bas lan mis ve 30 da ki ka son ra has ta la rin he mo di na mik ve ri le ri du - zel mis tir. Anah tar Ke li me ler: Kalp trans plan tas yo nu; kardiyotonik ajan lar; le vo si men dan ABS TRACT Primary graft failure is a major cause of early mortality after heart transplantation. Treatment alternatives include inotropes and mechanical assist devices. Levosimendan is a new cal - cium sensitizer presenting positive inotropic and vasodilator effect in the coronary, pulmonary and systemic vasculature. We report two patients who underwent orthotopic heart transplantation and suffered from low output syndrome. One of these cases was treated with a bolus dose levosimen - dan of 12 µg-1 . kg -1 and a 0.2 µg-1 . kg -1 . min-1 infusion rate in addition to classical inotropic agents.